IPO Preview | With no revenue one year after product launch, how does Ruichu Robotics convince the market to 'pay up'?

With a series of favorable policies for the surgical robotics industry being intensively rolled out since the beginning of this year, 2026 has become a pivotal turning point for the sector’s transition from pilot applications to large-scale commercialization.

Zhitong FinanceJul 6 11:07

Rui Chu Robotics IPO: Core Product Generates Zero Revenue One Year After Launch, Yet Valuation Reaches RMB 3.07 Billion with Redemption Liabilities Looming

Recently, Shanghai Rui Chu Robotics Co., Ltd. (hereinafter referred to as "Rui Chu Robotics") formally submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with Everbright Securities International acting as its sole sponsor. Powered by its self-developed CT-guided percutaneous puncture surgical robot, the RC120, Rui Chu Robotics has rapidly risen in the percutaneous puncture surgical robotics segment and ranked second domestically in terms of trial installations in 2024. Following its Series B financing, the company’s valuation surged to RMB 3.07 billion. However, behind its second-place industry ranking and soaring capital valuation lies an underlying operational crisis: its core product, approved for more than a year, has yet to generate any revenue, and the company has accumulated nearly

Sina FinanceJun 12 16:34

IPO News | Rui Chu Robotics Plans Hong Kong IPO; CSRC Requests Clarification on Income Tax Payments by Transferors in Equity Transfer Transactions

On May 29, the China Securities Regulatory Commission (CSRC) published supplementary documentation requirements for overseas listings (May 25, 2026 – May 29, 2026).

Zhitong FinanceMay 29 19:20